• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

    1.280 +0.010 (+0.79%)
    Streaming Delayed Price Updated: 1:43 PM EDT, Jun 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 22,023
    Open 1.270
    Bid (Size) 1.260 (200)
    Ask (Size) 1.280 (500)
    Prev. Close 1.270
    Today's Range 1.250 - 1.280
    52wk Range 1.230 - 12.23
    Shares Outstanding 11,586,406
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
    From Tempest Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    -56.6%
    -56.6%
    1 Month
    -34.0%
    -34.0%
    3 Month
    -46.7%
    -46.7%
    6 Month
    -59.4%
    -59.4%
    1 Year
    -85.6%
    -85.6%

    More News

    Read More
    News headline image
    Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Reports Year End 2025 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Tempest Therapeutics Announces Up To $6 Million Private Placement
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
    From Tempest Therapeutics
    Via GlobeNewswire
    Wednesday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
    From Tempest Therapeutics
    Via GlobeNewswire
    The market is filled with gapping stocks in Thursday's session. ↗
    Via Chartmill
    News headline image
    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition
    Via MarketMinute
    News headline image
    TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction ↗
    Via Stocktwits
    News headline image
    Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast ↗
    Via Benzinga

    Frequently Asked Questions

    Is Tempest Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Tempest Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Tempest Therapeutics, Inc. - Common Stock trade on?
    Tempest Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Tempest Therapeutics, Inc. - Common Stock?
    The ticker symbol for Tempest Therapeutics, Inc. - Common Stock is TPST on the Nasdaq Stock Market
    What is the current price of Tempest Therapeutics, Inc. - Common Stock?
    The current price of Tempest Therapeutics, Inc. - Common Stock is 1.280
    When was Tempest Therapeutics, Inc. - Common Stock last traded?
    The last trade of Tempest Therapeutics, Inc. - Common Stock was at 06/11/26 01:43 PM ET
    What is the market capitalization of Tempest Therapeutics, Inc. - Common Stock?
    The market capitalization of Tempest Therapeutics, Inc. - Common Stock is 14.83M
    How many shares of Tempest Therapeutics, Inc. - Common Stock are outstanding?
    Tempest Therapeutics, Inc. - Common Stock has 15M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.